Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.5755 +0.0173 (+3.10%)

Streaming Delayed Price Updated: 1:43 PM EST, Feb 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	274,577
Open	0.5642
Bid (Size)	0.5734 (100)
Ask (Size)	0.5848 (24,700)
Prev. Close	0.5582
Today's Range	0.5642 - 0.5897
52wk Range	0.5351 - 5.140
Shares Outstanding	9,362,444
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Today 3:33 EST

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Class Action Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

January 30, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Performance

YTD	-15.2%	-15.2%
1 Month	-15.2%	-15.2%
3 Month	-86.4%	-86.4%
6 Month	-80.2%	-80.2%
1 Year	-80.2%	-80.2%

More News

ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 29, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Why Did Vistagen Stock Tank 82% Today? ↗

December 17, 2025

Via Stocktwits

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

January 29, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

January 28, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

January 27, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 27, 2026

From Schall Law

Via GlobeNewswire

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

January 26, 2026

From Robbins LLP

Via Business Wire

VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

January 24, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit

January 24, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

January 22, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 20, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

January 20, 2026

From Robbins LLP

Via GlobeNewswire

VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm

January 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

January 16, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

January 16, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 16, 2026

From The Schall Law Firm

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

January 16, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

January 15, 2026

From Robbins LLP

Via Business Wire

These stocks have an unusual volume in today's session ↗

December 22, 2025

Via Chartmill

On Friday, there are stocks with unusual volume. Let's take a look. ↗

December 19, 2025

Via Chartmill

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

December 18, 2025

Via Chartmill

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

December 17, 2025

From Vistagen

Via Business Wire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?

Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?

Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?

The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market

What is the current price of Vistagen Therapeutics, Inc. - Common Stock?

The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.5755

When was Vistagen Therapeutics, Inc. - Common Stock last traded?

The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 02/02/26 01:43 PM ET

What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?

The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 5.39M

How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?

Vistagen Therapeutics, Inc. - Common Stock has 5M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.